GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS

Global And China Osteoporosis Drugs MarketSize and Trends

The Global and China Osteoporosis Drugs Market is estimated to be valued at US$ 14.6 Bn in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Figure 1. Global and China Osteoporosis Drugs Market Share (%), by Drug Type, 2023

Global and China Osteoporosis Drugs Market– Driver

• Increased mergers and acquisition scenarios between key market players: The growing incidences of mergers and acquisition scenarios between key market players  are a major factor driving the growth of the market over the forecast period. For instance, in December 2022,  Amge Inc- a U.S.-based multinational biopharmaceutical company acquired Horizon Therapeutics- a developer of drugs for rare, autoimmune, and severe inflammatory disease, to expand their product portfolio and offerings.
• Increased product approvals by regulatory bodies: The increasing product approvals by regulatory bodies of respective countries can drive the growth of the global and China osteoporosis drugs market. For instance, on February 06, 2023, The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for a proposed biosimilar to denosumab. Denosumab is a RANK ligand inhibitor for the treatment of postmenopausal women with osteoporosis at high risk for fracture;...

Global and China Osteoporosis Drugs Market-

Market Trends

The global and China osteoporosis drugs market report is segmented into drug type, route of administration , distribution channel, and region.